Relative Potency of Xenobiotic Estrogens in an Acute in Vivo Mammalian Assay

S.R. Milligan, A.V. Balasubramanian, and J.C. Kalita
Physiology, Biomedical Sciences Division, King’s College, London, United Kingdom

The in vivo effects of xenoestrogens are of interest in relation to their potential health risks and/or beneficial effects on humans and animals. However, the apparent in vivo potency of the examined response can be confounded by a short half-life, and the metabolism of estrogens is very dependent on the nature of conversion and/or inactivation. To minimize such variables, we examined the estrogenic potency of a range of xenoestrogens in an acute in vivo assay—the stimulation of increased uterine vascular permeability in ovariectomized mice 4 hr after subcutaneous administration. While estradiol (E2) and estriol (E3, a relatively weak natural estrogen) readily induced vascular responses [median effective dose (ED50) <10^{-4} mol], much higher amounts of xenoestrogens were required. Bisphenol A was about 10,000-fold less potent than E2 and E3 and octylphenol and nonylphenol were about 100,000-fold less potent; dioctyl phthalate, benzy1 butyl phthalate, dibutyl phthalate, and trichlorinated biphenol produced no effect. Coumestrol was the most active phytoestrogen, with an ED50 between 10^{-6} and 10^{-5} mol; genistein was about 10-fold less potent than coumestrol, and neither daidzein nor formononetin produced any marked effect, even at doses up to 10^{-3} mol. All increases in vascular permeability could be blocked by the pure antiestrogen ICI 182,780. There was no evidence that any of the compounds could act as an antiestrogen in this assay or that they could exert synergistic effects in combination. These results indicate that even short-term exposure to most of the xenobiologic estrogens can induce typical estrogenic effects in vivo, but their estrogenic potency is very weak even when assessed in an acute response.

Key words: environmental estrogens, phytoestrogens, uterine, vascular permeability, xenobiologic.

Environ Health Perspect 106:23–26 (1998). [Online 2 January 1998]
http://ehpnet1.niehs.nih.gov/docs/1998/106p23-26milligan/abstract.html

There is considerable public and scientific interest in the potential effects of the exposure of humans and other animals to environmental estrogens. These nonsteroidal estrogenic compounds essentially fall into two categories: they are derived from either dietary sources or industrial sources. The recent surge of interest in this area has largely come from the use of very sensitive in vitro assays, which have allowed the identification of weak estrogenic activity in many industrially derived chemicals (1). This has been coupled with natural and experimental observations of estrogenic effects in aquatic animals (e.g., fish) living under continuous exposure to the compounds (2). The possible health benefits of diets rich in phytoestrogens has provided an additional and alternative focus of attention (3).

While the existence of dietary and environmental compounds with estrogenic activity is clear, speculation linking them to epidemiological data on fertility, reproductive abnormalities, and disease is severely hampered by our very poor understanding of the in vivo biological activity of these compounds. In vitro assays have established that all the compounds are relatively weak estrogens, with both binding affinity to the estrogen receptor and in vitro biological activity usually <1/1,000 of estradiol (4). However, it is difficult to extrapolate from such in vitro data to the in vivo situation in which the biological activity is dependent on the complex in vivo pharmacokinetics associated with uptake, distribution, metabolism, and excretion.

There have been virtually no systematic, detailed studies of the nature and time course of the estrogenic effects of these chemicals in vivo in mammals. As a first stage to assessing the in vivo estrogenic activity, this study was undertaken to establish the relative potency of the compounds in an acute in vivo mammalian assay. In vivo, the complex pattern of estrogenic action on the uterus can be dissociated into a group of early responses (e.g., increased vascular permeability, uterine edema, uterine eosinophilia) and a group of later responses (a host of biochemical changes leading to cell division, differentiation, and uterine growth) (5).

Estimates of estrogenic potency are markedly affected depending on which of these two groups of responses are used as the baseline. Thus while estriol and estradiol are relatively similar when assessed in terms of the ability of single subcutaneous (sc) injections to induce early uterine responses, such single exposures to estriol are considerably less effective than estradiol in producing sustained effects due to the rapid dissociation of estriol from its receptor (5).

The rationale behind this study was to use one of the early specific estrogen-stimulated responses as the basis for comparing relative estrogenic potencies. This was based on the assumption that estimates of potency from early responses would minimize complications arising from metabolism, clearance, rapid dissociation from receptors, etc. The early response chosen was the rapid increase in uterine vascular permeability [apparent within 15–30 min, with very large responses (three- to fourfold increase) within 3–4 hr] of estrogen exposure (5,6). This response has the advantage that it can be readily quantified by monitoring the extravasation of intravenously administered [125I]-labeled human serum albumin (7).

Methods

Animals. Female Swiss albino mice (A. Tuck & Son Ltd., Battlesbridge, Essex, U.K.), approximately 3 months of age and weighing 25–35 g, were maintained under constant conditions of lighting (lights on from 0600 hr to 1800 hr) and temperature (21 ± 1°C) and fed on a pelleted diet (Economy Rodent Maintenance, Essex, UK) ad libitum. All experiments were performed on ovariectomized animals. Ovariectomies were performed under tribromoethanol anesthesia at least 2 weeks before the start of each experiment. All test compounds were administered by sc injection in a volume of 0.1 ml.

Chemicals. 17β-Estradiol (E2), genistein (4’,5,7-trihydroxyisoflavone), and daidzein (4’,7-dihydroxyisoflavone) were obtained from Sigma Chemical Co. Ltd. (Dorset, U.K.). Coumestrol (3,9-dihydroxy-6β-benzofuro-[3,2-g]-1benzopyran-6-one) and formononetin (7-hydroxy-4’-methoxyisoflavone) were obtained from Acrós Organics (Springfield, NJ) and Extrasynthese (Genay, France), respectively. 4-Nonylphenol, 4-tert-octylphenol, bisphenol A [2,2-bis(4-hydroxyphenyl)propane, dioctyl phthalate, benzy1 butyl phthalate, and dibutyl phthalate were obtained from Aldrich Chemical Co. Ltd. (Gillingham, U.K.). Trichlorinated biphenol (TCB; 3,4,3’,4’-tetrachlorobiphenyl) was a gift from P. Darbre (University of Reading, Reading, U.K.). Stock solutions of the chemicals were normally dissolved in ethyl alcohol or DMSO. The injection vehicle was either arachis oil (phytoestrogens) or saline (others)

Address correspondence to S.R. Milligan, Physiology, Biomedical Sciences Division, King’s College, Strand, London, WC2R 2LS, United Kingdom.

We are grateful to the Medical Research Council for support. J.C.K., a Commonwealth scholar from India, was supported by the British Council.

Received 10 June 1997; accepted 11 September 1997.
containing 25% DMSO or alcohol. The pure antiestrogen ICI 182,780 (a gift from A. Wakeling, Zeneca Pharmaceuticals, Macclesfield, U.K.) was dissolved in alcohol to give a stock solution of 10 mg/ml ethanol and administered in an arachis oil vehicle.

**Vascular permeability changes in response to test treatment.** A quantitative index of the permeability of the uterine vasculature 4 hr after sc injection of the test compound was obtained from the leakage of radiolabeled albumin from the circulation (7,8). In brief, 3.5 hr after the injection of the test substance, 50 μl 0.5 μCi [125I]-labeled human serum albumin was injected into the jugular vein of mice anesthetised with tribromoethanol. Thirty minutes later, a blood sample was drawn from the suborbital canthal sinus with a heparinized capillary pipette and the animals were killed by cervical dislocation. The blood sample was centrifuged to provide a 100 μl plasma sample. The uteri and a sample of thigh muscle were removed, briefly washed in saline, and weighed. The radioactivity in the uterus, plasma sample, and muscle was determined. Previous studies on the uterus (8,9,10) have suggested that the blood volume of the uterus is very much smaller than the albumin space (after a circulation time of 30 min) and that the extravascular albumin space is the major determinant of the total tissue albumin space. The tissue-specific extravascular albumin volume (EAV) was expressed as a ratio of the [125I] counts per minute per milligram of tissue to [125I] counts per minute per microliter of plasma and used as an index of tissue vascular permeability (7).

**Analyses of results.** Results were expressed as mean ± standard error (SE) and analyzed using analysis of variance (ANOVA).

**Results**

**Experiment 1—Dose–response effects of xenobiotic estrogens on uterine vascular permeability.** Ovariectomized mice were injected with one of the following in the volume of 0.1 ml saline: control vehicle, E2 (10-12 -10-9 mol), or various doses of E2, coumestrol, genistein, daidzein, formononetin, nonylphenol, octylphenol, bisphenol A, diocyl phthalate, dibutyl phthalate, and benzyl butyl phthalate; uterine vascular permeability was determined 4 hr later. The results are shown in Figures 1 and 2. E2 induced a marked increase in uterine vascular permeability at injected doses down to 10-10 mol. The highest doses of E2 produced a fourfold increase in extravascular albumin volumes (>22 μl/mg compared to < 4 μl/mg for controls), with about 10-9-10-10 mol being required to produce half-maximal (EAV=13 μl/mg) stimulation. E2 was also very effective in stimulating vascular permeability, with a median effective dose (ED50) <10-9 mol. All the other industrial compounds were required at considerably higher doses before any increase in uterine vascular permeability was observed (Fig. 1), and some showed no effect at all. Compared to E2, bisphenol A was about 10,000 times less effective in inducing the uterine vascular response (ED50 =10-5 mol), and octylphenol and nonylphenol were about 100,000 times less effective (ED50 =10-4 mol). The three phthalates, diocyl phthalate, benzyl butyl phthalate, and dibutyl phthalate (10-4 mol), and trichlorinated biphenol (10-5 mol) produced no significant effect on uterine vascular permeability.

Coumestrol was the most potent of the phytostrogens (ED50 between 10-6 and 10-7 mol), but still required 100-1,000-fold higher doses of the compound than E2 (Fig. 2). The amount of genistein required to induce the vascular response was about 10-fold higher again, while neither daidzein nor formononetin produced any marked effects, even when given at doses up to 10-5 mol.

**Experiment 2—The ability of the antiestrogen ICI 182,780 to inhibit estrogen-induced increases in uterine vascular permeability.** Ovariectomized mice were subjected to daily sc injections of 100 μg ICI 182,780 for 4 days. One hour after the last injection, the mice were given a single sc injection of one of the following: E2 (at doses of 10-11, 10-10, and 10-9 mol), E2 (10-9 mol), coumestrol (10-7 mol), genistein (10-6 mol), nonylphenol (10-4 mol), octylphenol (10-4 mol), and bisphenol A (10-5 mol); vascular permeability was determined 4 hr later. Pretreatment with the antiestrogen ICI 182,780 suppressed the increase in vascular permeability induced by the estradiol (10-9 mol) and the lower dose of estradiol (<10-10 mol). The antiestrogen suppressed the vascular responses to all the other substances tested (Table 1). There were no significant effects of the antiestrogen on the vascular permeability in the control tissue.

**Experiment 3—The effect of low levels of environmental estrogens on estradiol-stimulated increases in vascular permeability.** The possibility that low doses of xenobiotic estrogens (i.e., below the level required to induce an estrogenic response) might act as antiestrogens was investigated by examining the effect of a nonstimulatory dose of the compounds in combination with a stimulatory dose of E2. Ovariectomized mice were injected sc with E2 (10-10 mol) together with either coumestrol (10-8 mol), daidzein (10-5 mol), formononetin (10-5 mol), nonylphenol (10-5 mol), octylphenol (10-6 mol), and bisphenol A (10-7 mol), diocyl phthalate (10-4 mol),

**Figure 1.** The dose–response effects of 17β-estradiol, estral, and the environmental estrogens bisphenol A, octylphenol, and nonylphenol on uterine vascular permeability 4 hr after subcutaneous administration in ovariectomized mice. Saline controls were included for each experimental data point. Vascular permeability was determined by the extravascular accumulation of [125I]-albumin and was expressed as extravascular albumin volume (EAV; see Methods). The data are expressed as mean ± standard error (n = 6–12). Where no error bars are shown, the errors were smaller than the symbol. Statistical significance was determined by comparison with the controls.

*p<0.05; **p<0.01; ***p<0.001.

**Figure 2.** The dose–response effects of 17β-estradiol, estral, and the phytostrogens coumestrol, genistein, and daidzein on uterine vascular permeability 4 hr after subcutaneous administration in ovariectomized mice. Saline controls were included for each experimental data point. Vascular permeability was determined by the extravascular accumulation of [125I]-albumin and was expressed as extravascular albumin volume (EAV; see Methods). The data are expressed as mean ± standard error (n = 6–12). Where no error bars are shown, the errors were smaller than the symbol. Statistical significance was determined by comparison with the controls.

*p<0.05; **p<0.01; ***p<0.001.
Table 1. The ability of the antiestrogen ICI 182,780 to inhibit estrogen-induced increases in uterine vascular permeability

| Compound administered (mol) | Number of mice | Uterine weight (mg) | Uterine vascular permeability ratio (%) | Muscle vascular permeability ratio (%) |
|-----------------------------|----------------|---------------------|----------------------------------------|---------------------------------------|
| Control                     | 12             | 13.00 ± 1.25        | 4.26 ± 0.51                            | 0.64 ± 0.08                           |
| ICI 182,780                 | 6              | 8.47 ± 0.01         | 4.20 ± 0.27                            | 0.47 ± 0.04                           |
| 17β-Estradiol 10-12         | 6              | 16.82 ± 0.02        | 3.35 ± 0.39                            | 0.5 ± 0.04                            |
| 17β-Estradiol 10-12 + ICI   | 6              | 10.05 ± 0.01        | 3.40 ± 0.12                            | 0.44 ± 0.06                           |
| 17β-Estradiol 10-16         | 6              | 18.72 ± 0.01        | 17.63 ± 2.04                           | 0.47 ± 0.05                           |
| 17β-Estradiol 10-6 + ICI    | 6              | 13.23 ± 1.32        | 7.83 ± 1.73*                           | 0.61 ± 0.03                           |
| 17β-Estradiol 10-5 + ICI    | 6              | 17.58 ± 1.83        | 25.79 ± 1.90                           | 0.42 ± 0.02                           |
| 17β-Estradiol 10-4 + ICI    | 6              | 16.12 ± 0.01        | 22.19 ± 2.50                           | 0.46 ± 0.05                           |
| Carnosol 10-6              | 6              | 19.58 ± 1.85        | 28.40 ± 2.98                           | 0.50 ± 0.01                           |
| Carnosol 10-5 + ICI         | 6              | 15.10 ± 0.01        | 4.31 ± 0.36*                           | 0.57 ± 0.04                           |
| Genistein 10-6             | 6              | 15.96 ± 1.11        | 25.43 ± 1.92                           | 0.60 ± 0.08                           |
| Genistein 10-5 + ICI        | 6              | 13.16 ± 0.09        | 5.92 ± 0.54*                           | 0.55 ± 0.04                           |
| Estradiol 10-6              | 6              | 26.5 ± 0.02         | 18.27 ± 2.70                           | 0.54 ± 0.04                           |
| Estradiol 10-5 + ICI        | 6              | 16.32 ± 0.02        | 12.8 ± 1.46*                           | 0.51 ± 0.04                           |
| Nonylphenol 10-6            | 6              | 18.90 ± 0.01        | 16.74 ± 1.06                           | 0.47 ± 0.05                           |
| Nonylphenol 10-4 + ICI      | 6              | 15.08 ± 0.03        | 4.53 ± 1.17*                           | 0.65 ± 0.11                           |
| Octylphenol 10-6            | 6              | 12.60 ± 1.52        | 18.45 ± 3.49                           | 0.53 ± 0.06                           |
| Octylphenol 10-4 + ICI      | 6              | 13.07 ± 0.01        | 5.7 ± 1.0*                             | 0.44 ± 0.04                           |
| Bisphenol A 10-5           | 6              | 16.50 ± 1.20        | 15.18 ± 2.40                           | 0.42 ± 0.02                           |
| Bisphenol A 10-4 + ICI      | 6              | 8.15 ± 0.03         | 3.67 ± 0.48*                           | 0.45 ± 0.02                           |

Ovariectomized mice were subjected to daily subcutaneous (sc) injections of 100 μg ICI 182,780 for 4 days. One hour after the fourth injection, the test compound was administered sc. Saline controls were included for each experimental point. Vascular permeability was determined by the extravascular accumulation of [14C]albumin and was expressed as a ratio (mean ± standard error) of the [14C] counts per minute per milligram of tissue to [125I] counts per minute per microliter of plasma. Thigh muscle was the control tissue.

**Significantly lower than the test compound alone (p<0.001).**

Discussion

The availability of very sensitive in vitro bioassays for estrogens has led to the identification of estrogenic activity in many industrial (11,12) and plant-derived compounds (13). However, even in vitro assays, the estrogenic activity of these compounds is usually less than 1/1,000–1/100,000 that of E2 (1,4,11–13). Our data is in general agreement with published data on the in vitro potency of the xenobiotic estrogens, emphasizing that these compounds can only exert significant estrogenic activity when present in very large quantities. Bisphenol A appears to be one of the more potent xenobiotic estrogens (14,15); a recent in vivo study in rats examining prolactin secretion (14) suggested that bisphenol A was only 100–500 fold less active than E2, while bisphenol A potency in vitro was 1,000–5,000-fold less than E2. In the present study, bisphenol A was about 10,000-fold less potent than E2.

These observations, coupled with the present observations, suggest that in vitro potencies of xenobiotic estrogens may not be an accurate guide to in vivo potencies, and estimates of in vivo potency will depend on the assay used.

The in vivo estrogenic potency of xenobiotic estrogens has received rather superficial attention, with results largely based on uterine growth after daily sc injections (16) or after administration by gavage (17). However, the relative potency of estrogenic compounds depends on a number of factors, including the route of administration and the nature of the response monitored. The particular problem of using uterine growth responses to assess estrogenic potency is well illustrated by comparing the effects of E2 and E3, while single sc injections of either of these hormones are very effective in inducing rapid uterine responses (that occur within a few hours of administration). E2 is unable to mimic E2 in terms of the uterine growth response measured at 24 hr after injection (5). Such differences in estrogenic responses led to E2 being described as a weak estrogen (18). However, the apparent low potency of single injections of E3 to induce uterine growth hides the biological reality of the estrogenic response. E2 is fully effective in producing the complete range of estrogenic responses when it is given as rapidly repeated injections (5) or as slow-release implants (19). These apparent differences between E2 and E3 in terms of their potency to induce acute and sustained responses highlight the difficulty of interpreting assessments of estrogenic potency by just single in vivo assay methods. In contrast to the long-term nature of uterine growth assays, the increase in uterine vascular permeability is an acute, rapid, easily monitored response of the uterus to estrogenic stimulation (7). The estrogen receptor-mediated nature of this response was confirmed in the present study by the ability of the pure antiestrogen ICI 182,780 to block the responses induced by E2, E3, and other compounds. The present study provides a direct indication of the acute in vivo potencies of a variety of dietary and industrial estrogenic compounds on an important target site for estrogens in female mammals. The results indicate that, even when measured in terms of their ability to induce acute responses, the activity of such compounds is very low in comparison with established estrogens like E2 and E3.

The relative potency of any of the environmental estrogens compared to E2 and E3 in this acute assay is particularly interesting. While E3 is a relatively weak estrogen in terms of any long-term growth responses to acute exposures, it is almost as effective as E2 in inducing rapid estrogenic effects in the uterus. However, even in this rapid in
vivo assay that allows the estrogenic activity of the relatively weak E₃ to be exposed, the potency of all the weak environmental estrogens was considerably lower. This would tend to emphasize that prolonged in vivo estrogenic responses to such compounds are unlikely to occur unless the exposures are both considerable and extended; this is currently under investigation. However, the possibility that acute exposures to these compounds may induce significant, although short-term, estrogenic responses should not be underestimated. Rapid responses to estrogens are an important feature of a number of reproductive processes, such as control of the cell cycle (3) and the sensitivity of the uterus to an implanting blastocyst (20); exogenous estrogenic agents may be able to either mimic endogenous estrogens and/or provide a disturbance to the sequence of endogenous estrogenic stimulation essential for the normal pattern of uterine responses.

References
1. Soto AM, Lin TM, Justice H, Silvia RM, Sonnenschein C. An “in culture” bioassay to assess the estrogenicity of xenobiotics (E-Screen). In: Chemically-induced Alterations in Sexual and Functional Development: The Wildlife/Human Connection (Colborn T, Clements C, eds). Princeton, NJ:Princeton Scientific Publishing, 1992:295-309.
2. Purdom CE, Hardiman PA, Bye VJ, Eno NC, Tyler CR, Sumpter JP. Estrogenic effects of effluents from sewage treatment works. Chem Ecol 4:275-85 (1994).
3. Knight DC, Eden JA. A review of the clinical effects of phytoestrogens. Obstet Gynecol 87:887-904 (1996).
4. White R, Jobling S, Hoare SA, Sumpter JP, Parker MG. Environmentally persistent alkylphenoxy compounds are estrogenic. Endocrinology 98:220-230 (1994).
5. Martin L, Pollard JW, Fagg B. Oestradiol-17β and the proliferation and death of uterine cells. J Endocrinol 89:103-115 (1976).
6. Cohen PE, Milligan SR. Silastic implants for delivery of oestriol to mice. J Reprod Fertil 99:219-223 (1993).
7. Arvidson NG. Early oestrogen-induced changes in uterine albumin exchange in mice. Acta Physiol Scand 100:325-331 (1977).
8. Milligan SR. The sensitivity of the uterus of the mouse and rat to intraluminal instillation. J Reprod Fertil 79:251-259 (1987).
9. Milligan SR, Mirembe FM. Time course of changes in uterine vascular permeability associated with the development of the decidual cell reaction in ovariectomized, steroid-treated rats. J Reprod Fertil 70:1-6 (1984).
10. Milligan SR, Mirembe FM. Intraluminally injected oil induces changes in vascular permeability in the "sensitised" and "non-sensitised" uterus of the mouse. J Reprod Fertil 74:95-104 (1985).
11. Jobling S, Reynolds T, White R, Parker MG, Sumpter JP. A variety of environmentally persistent chemicals, including some phthalate plasticizers, are weakly estrogenic. Environ Health Persect 103:582-587 (1995).